According to the findings of the study, the absence of TLR4 inhibits the progression of neuroinflammation associated with PD via regulation of the NF-κB, activator protein 1 (AP-1), and inflammasome pathways suggesting that this receptor has the potential to be an effective therapeutic target in neurodegenerative diseases [113]. Here, NFKB1 is linked to Parkinson disease.